Wockhardt gets FDA nod for generic Dacogen
Wockhardt recently received the Food and Drug Administration’s blessing for its generic Dacogen (decitabine 50 mg injection). The product, a generic of Otsuka's branded drug, is used to treat certain forms of cancer.
Decitabine is used to treat myelodysplastic syndromes, a group of cancers in which immature blood cells in the bone marrow do not mature and therefore do not become healthy blood cells.
The product had a market value of $120 million, according to February 2019 IQVIA data.
"This is the third FDA approval for an oncology product for Wockhardt during the past three months, and has added to our growing portfolio of cancer drugs," Wockhardt Group founder and chairman Habil Khorakiwala, said, adding, "Wockhardt has been sustaining growth in the U.S. and worldwide through an increasing portfolio of specialty products including oncology drugs.”
Wockhardt said it would be launching this product in the United States shortly.
Decitabine is used to treat myelodysplastic syndromes, a group of cancers in which immature blood cells in the bone marrow do not mature and therefore do not become healthy blood cells.
The product had a market value of $120 million, according to February 2019 IQVIA data.
"This is the third FDA approval for an oncology product for Wockhardt during the past three months, and has added to our growing portfolio of cancer drugs," Wockhardt Group founder and chairman Habil Khorakiwala, said, adding, "Wockhardt has been sustaining growth in the U.S. and worldwide through an increasing portfolio of specialty products including oncology drugs.”
Wockhardt said it would be launching this product in the United States shortly.